



The Company Announcements Platform  
ASX Ltd  
Sydney NSW 2000

## **PHYLOGICA AND ROCHE EXTEND COLLABORATION TO EVALUATE POTENTIAL FOR PHYLOMER® DELIVERY TO BRAIN**

PERTH, AUSTRALIA: May 23, 2011 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today an extension of its collaboration with the Swiss Pharmaceutical company Roche relating to cell-penetrating peptides derived from Phylogica's Phylomer drug discovery platform. Under the terms of the extended agreement, Phylogica has granted Roche an option to license a specific Phylomer peptide with demonstrated cell penetration activity for application to delivery across the blood-brain barrier.

"Following the success of the first stage of our research collaboration with Roche, we are delighted to have entered a new agreement that extends our relationship to blood-brain delivery of peptides. In partnership with Roche, we have identified unique cell-penetrating Phylomer peptides, some of which have the potential to cross the blood-brain barrier and could be used to develop novel treatments for neurological diseases. The discovery of biological drugs that can target neuronal cells has been a real challenge for the pharmaceutical industry in the past and so we are excited to be moving forward with Roche in this area."

**-ends-**

### **For further information, please contact:**

Nick Woolf  
CFO & VP, Corporate Development  
Tel: +61 417 986 005  
[nwoolf@phylogica.com](mailto:nwoolf@phylogica.com)

Rudi Michelson  
Monsoon Communications  
Tel + 61 3 9620 3333

### **About Phylogica**

Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia, and Oxford, UK, with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics. The Company was incorporated in 2001 as a spin out from the Telethon Institute for Child Health Research (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). The Company's drug discovery platform is based on its proprietary Phylomer® libraries of natural peptides, which have been optimised by evolutionary selection to have stable drug-like structures. Phylogica

PO Box 8207, Subiaco East, Western Australia 6008  
Suite 3, 257 York Street, Subiaco, Western Australia 6008  
Tel: +61 8 9382 8888 Fax: +61 8 9382  
[www.phylogica.com](http://www.phylogica.com)  
ABN 48 098 391 961

offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer<sup>®</sup> libraries and proprietary screening technologies. Its current partners include Roche, MedImmune (the worldwide biologics unit of AstraZeneca) and Pfizer.

### **About Phylomer<sup>®</sup> Peptides**

Phylomer peptides are derived from biodiverse natural sequences, which have been selected by evolution to form stable structures, which can bind tightly, and specifically to disease associated target proteins, both inside and outside cells. Suitable targets for blockade by Phylomers include protein interactions that promote multiple diseases, such as infectious diseases, cancer, autoimmunity and heart disease. Phylomer peptides can have drug-like properties, including specificity, potency and thermal stability, and are capable of being produced by synthetic or recombinant manufacturing processes. Phylomer peptides are also readily formulated for administration by a number of means, including parenteral or intranasal delivery approaches.